1-ó4-(溴甲基)苯-1H-吡唑 | 368869-85-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-ó4-(溴甲基)苯-1H-吡唑
• 中文别名: 1-[4-(溴甲基)苯基]-1H-吡唑
• 英文名称: 1-(4-(bromomethyl)phenyl)-1H-pyrazole
• 英文别名: 1-[4-(Bromomethyl)Phenyl]-1H-Pyrazole；1-[4-(bromomethyl)phenyl]pyrazole
• CAS: 368869-85-6
• 化学式: C₁₀H₉BrN₂
• 分子量: 237.099
• InChiKey: PHNRBSHOFSWNII-UHFFFAOYSA-N

物化性质

• 熔点：
  77-79°C
• 沸点：
  315.3±25.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R36/37/38
• 储存条件：
  存储条件：2-8°C，密封保存，并保持干燥。

SDS

Name:	1-[4-(Bromomethyl)phenyl]-1h-pyrazole 95+% Material Safety Data Sheet
Synonym:
CAS:	368869-85-6

Section 1 - Chemical Product MSDS Name:1-[4-(Bromomethyl)phenyl]-1h-pyrazole 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
368869-85-6	1-[4-(Bromomethyl)phenyl]-1H-pyrazole	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 368869-85-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: perceptible odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 77 - 79 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9BrN2
Molecular Weight: 237.1

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 368869-85-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-[4-(Bromomethyl)phenyl]-1H-pyrazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 368869-85-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 368869-85-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 368869-85-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-ó4-(溴甲基)苯-1H-吡唑 在 盐酸 、 sodium hydride 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate
  参考文献：
  名称：

  选择性，非前列腺素类EP2受体激动剂的治疗青光眼的鉴定：奥米尼帕克及其前药奥米尼帕克异丙基

  摘要：

  预期EP2受体激动剂是有效的降眼压药。然而，已经提出对其他EP受体亚型的激动作用可能导致不良作用。通过药物化学的努力，我们确定了带有（吡啶-2-基氨基）乙酸部分的支架是有前途的EP2选择性受体激动剂。（6-（（4-（吡唑-1-基）苄基）（吡啶-3-基磺酰基）氨基甲基）吡啶-2-基氨基）乙酸13ax（omidenepag，OMD）对人EP2受体具有有效的选择性活性（ h-EP2）。低剂量的奥米地帕异丙（OMDI）（一种13ax的前药）可降低正常眼压性猴子的眼内压（IOP）。OMDI被选为治疗青光眼的临床候选药物。

  DOI：

  10.1021/acs.jmedchem.8b00808
• 作为产物：
  描述：

  1-(4-羟甲基苯基)吡唑 在 三溴化磷 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以1.25 g的产率得到1-ó4-(溴甲基)苯-1H-吡唑
  参考文献：
  名称：

  [EN] SUBSTITUTED AZACYCLES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] AZACYCLES SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR MUSCARINIQUE M1

  摘要：

  本发明涉及化合物(I)的公式，或其同位素形式、立体异构体、互变异构体或其药学上可接受的盐，作为肌动蛋白M1受体正向变构调节剂（M1 PAMs）。本发明描述了制备方法、药物组合物、组合物的使用以及化合物公式(I)、其立体异构体、同位素形式或其药学上可接受的盐的使用。 (I)

  公开号：

  WO2019102365A1
• 作为试剂：
  描述：

  2-amino-5-bromo-N-((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)-3,4-dimethylbenzamide 在 盐酸 、 1-ó4-(溴甲基)苯-1H-吡唑 、 bis-triphenylphosphine-palladium(II) chloride 、 四(三苯基膦)钯 、 potassium acetate 、 sodium carbonate 、 sodium nitrite 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 6.0h， 生成 3-((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)-7,8-dimethyl-6-(4-(1H-pyrazol-1-yl)benzyl)-1,2,3-benzotriazin-4(3H)-one
  参考文献：
  名称：

  Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

  摘要：

  本发明提供了一种具有胆碱能肌动蛋白M1受体阳性变构调节剂活性的化合物，可能作为药物使用，例如作为预防或治疗阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、Lewy体痴呆等的药剂。本发明涉及一种由式（I）表示的化合物或其盐。在式（I）中，每个符号如所附说明书中所述。

  公开号：

  US10548899B2

文献信息

• [EN] NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] COMPOSÉS DE NAPHTHALÈNE CARBOXAMIDE, MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1
  申请人：MERCK SHARP & DOHME

  公开号：WO2011149801A1

  公开（公告）日：2011-12-01

  The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的萘甲酰胺化合物，它们是M1受体阳性变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• Design and Synthesis of γ- and δ-Lactam M₁ Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M₁-Selective PAM with Weak Agonist Activity
  作者：Jennifer E. Davoren、Michelle Garnsey、Betty Pettersen、Michael A. Brodney、Jeremy R. Edgerton、Jean-Philippe Fortin、Sarah Grimwood、Anthony R. Harris、Stephen Jenkinson、Terry Kenakin、John T. Lazzaro、Che-Wah Lee、Susan M. Lotarski、Lisa Nottebaum、Steven V. O’Neil、Michael Popiolek、Simeon Ramsey、Stefanus J. Steyn、Catherine A. Thorn、Lei Zhang、Damien Webb

  DOI：10.1021/acs.jmedchem.7b00597

  日期：2017.8.10

  series, compound 1 (PF-06827443), is a potent, low-clearance, orally bioavailable, and CNS-penetrant M1-selective PAM with minimal agonist activity. Compound 1 was tested in dose escalation studies in rats and dogs and was found to induce cholinergic AEs and convulsion at therapeutic indices similar to previous compounds with more agonist activity. These findings provide preliminary evidence that positive

  最近的数据表明，亚型选择性正变构调节剂（PAM）对毒蕈碱M 1受体的激活有助于先前归因于M 2和M 3激活的胃肠道（GI）和心血管（CV）胆碱能不良事件（AE）。这些研究是使用也表现出变构激动剂活性的PAM进行的，这有可能通过变构激动而不是变构调节直接激活可能是造成不良反应的原因。本文介绍了解决这一假设的内酰胺衍生的M 1 PAM的设计和合成。该系列的先导分子，化合物1（PF-06827443）是一种有效的，清除率低，口服可生物利用的且具有最小激动剂活性的CNS渗透性M 1选择性PAM。在大鼠和狗的剂量递增研究中对化合物1进行了测试，发现化合物1的胆碱能AE和惊厥的治疗指数与以前的具有更高激动剂活性的化合物相似。这些发现提供了初步的证据，即M 1的正构构调制足以引起胆碱能AE。
• SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
  申请人：Jones Robert M.

  公开号：US20110160243A1

  公开（公告）日：2011-06-30

  The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.

  本发明涉及某些取代的三环酸衍生物，其具有式(I)和药用可接受的盐，并表现出有用的药理性质，例如，作为S1P1受体的激动剂。本发明还提供了含有发明的化合物的药物组合物，以及使用发明中的化合物和组合物治疗与S1P1相关的疾病的方法，例如，银屑病、类风湿性关节炎、克罗恩病、移植排斥反应、多发性硬化症、系统性红斑狼疮、溃疡性结肠炎、I型糖尿病、痤疮、心肌缺血再灌注损伤、高血压肾病、肾小球硬化症、胃炎、多发性肌炎、甲状腺炎、白癜风、肝炎、胆汁性肝硬化、微生物感染及相关疾病、病毒感染及相关疾病、由淋巴细胞介导的疾病和障碍、自身免疫性疾病、炎症性疾病和癌症。
• [EN] PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE TYPE PYRAZOLO[4,3-C]CINNOLIN-3-ONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010096338A1

  公开（公告）日：2010-08-26

  The present invention is directed to pyrazolo [4,3-c] cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]咖啉-3-酮化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• Sulfonamides
  申请人：Galley Guido

  公开号：US20060014945A1

  公开（公告）日：2006-01-19

  The invention relates to compounds of the general formula in which R 1 , R 2 , R3, R 4 , R 2′ , R3′, R 4′ , R 5 , and X is —CHR— are as defined in the specification. The invention also provides pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures of such compounds. The invention further provides methods for the treatment of Alzheimer's disease or common cancers.

  该发明涉及一般式化合物，其中R1、R2、R3、R4、R2'、R3'、R4'、R5和X为规范中定义的—CHR—。该发明还提供药学上可接受的酸盐加合物，光学纯对映体，外消旋体和这类化合物的二对映异构体混合物。该发明还提供治疗阿尔茨海默病或常见癌症的方法。